TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2882736
Drug: Office-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based behavioral therapy
Study: 28031039
Drug: Attention training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention training using novel eye‐tracking technology and gaze‐contingent training paradigms, nine weekly home‐based sessions
Study: 28031039
Drug: Non‐gaze‐contingent age‐appropriate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐gaze‐contingent age‐appropriate videos, nine weekly home visits
Study: 19038848
Drug: atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin (10 mg/d) for 6 weeks
Study: 19038848
Drug: torcetrapib/atorvastatin (60/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: torcetrapib/atorvastatin (60/10 mg/d) for 6 weeks
Study: 17503980
Drug: Sertraline (25‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (25‐200 mg/day)
Study: 9812660
Drug: Colonic dialysis
Normalized name: colonial bent grass pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonic dialysis therapy with Chinese herbal medicine (from third day to eighth day)
Study: 9812660
Drug: Combined dihydroetorphine
Normalized name: Dihydroetorphine
DrugBank: Dihydroetorphine (DB01450)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dihydroetorphine (DHE) and methadon therapy
Study: 8588492
Drug: Periconceptional multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periconceptional multivitamin supplementation (including 0.8 mg folic acid)
Study: 3662586
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 200 micrograms twice daily
Study: 28892558
Drug: 18 mg
Normalized name: niacin 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg of selonsertib orally once daily for 24 weeks
Study: 28892558
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of selonsertib orally once daily for 24 weeks
Study: 1424176
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA, 50 mg once daily from Day 5 to Day 15) and ethinyl oestradiol (EE2, 30 micrograms once daily from Day 5 to Day 24 of the menstrual cycle)
Study: 4096742
Drug: Normal-release 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-release 10 mg nifedipine soft gelatine capsule (Pidilat)
Study: 20219584
Drug: GaAlAs laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: GaAlAs laser therapy (P = 100 mW, lambda = 830 nm, Ø = 0.06 cm(2), applied in 8 sessions with intervals of 48 hours)
Study: 17676201
Drug: Midazolam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.02 mg kg‐1) + Propofol (0.2 mg kg‐1) + Fentanyl (1 microgram kg‐1)
Study: 17676201
Drug: Midazolam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.02 mg kg‐1)
Study: 17676201
Drug: Midazolam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.02 mg kg‐1) + Propofol (0.2 mg kg‐1)
Study: 17676201
Drug: Midazolam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.02 mg kg‐1) + Fentanyl (1 microgram kg‐1)
Study: 11902739
Drug: 10 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg red blood cells
Study: 11902739
Drug: 20 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL/kg red blood cells
Study: 2523785
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (12 units injected subcutaneously)
Study: 414344
Drug: Floctafenine 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floctafenine 1.6 g daily
Study: 414344
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin 4.0 g daily
Study: 414344
Drug: Floctafenine 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floctafenine 1.6 g daily for 3-6 months
Study: 29298622
Drug: CoQ10 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (400 mg/day)
Study: 28879245
Drug: 8% capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% capsaicin cream
Study: 26237980
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine + auricular pressure (treatment group)
Study: 26237980
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (control group)
Study: 19706240
Drug: Celecoxib (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (selective COX-2 inhibitor) for 1 week
Study: 10717011
Drug: Etanercept (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (0.4 mg/kg subcutaneously twice weekly for up to three months)
Study: 9113213
Drug: Alcohol rehabilitation
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol rehabilitation program treatment
Study: 2870226
Drug: SMS 201-995,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS 201-995, 50 micrograms/h, continuous intravenous infusion
Study: 2975549
Drug: Glibenclamide and
Normalized name: Glibenclamide and metformin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide and Metformin
Study: 28475456
Drug: Oral brigatinib
Normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral brigatinib 90 mg once daily (arm A)
Study: 28475456
Drug: Oral brigatinib
Normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral brigatinib 180 mg once daily with a 7-day lead-in at 90 mg (arm B)
Study: 26145274
Drug: Taxes on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxes on low nutrient dense foods (e.g. sweetened beverages, candy, salty snacks)
Study: 18679669
Drug: Nebicapone 200
Normalized name: Nebicapone
DrugBank: Nebicapone (DB14849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebicapone 200 mg thrice daily for 9 days with racemic warfarin 25 mg single dose on day 4
Study: 18679669
Drug: Racemic warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic warfarin 25 mg single dose alone
Study: 14646973
Drug: Positive anticardiolipin
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive anticardiolipin antibody (ACLA) levels in adolescents in the case group (parents with MI<55 years)
Study: 14646973
Drug: Positive anticardiolipin
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive anticardiolipin antibody (ACLA) levels in parents of adolescents in the case group (parents with MI<55 years)
Study: 10715297
Drug: Vancomycin/Heparin/Ciprofloxacin flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin/Heparin/Ciprofloxacin flush solution (VHC)
Study: 10715297
Drug: Vancomycin/Heparin (VH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin/Heparin (VH)
Study: 3982273
Drug: Caffeine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (400 mg added to decaffeinated coffee)
Study: 29623447
Drug: Ritonavir-boosted lopinavir
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted lopinavir (LPV/r) based antiretroviral therapy (ART)
Study: 27029920
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (vancomycin or daptomycin)
Study: 27029920
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus 7 days of an anti‐staphylococcal β‐lactam (flucloxacillin, cloxacillin, or cefazolin)
Study: 20351334
Drug: vinflunine 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: vinflunine 320 mg/m² every 21 days
Study: 20351334
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m² every 21 days
Study: 17273677
Drug: Digital retinographer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital retinographer injecting 2 ml fluorescein at 10%
Study: 17273677
Drug: Conventional retinographer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional retinographer injecting 5 ml sodium fluorescein at 10%
Study: 11896774
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin C preparation (10% ascorbic acid and 7% tetrahexyldecyl ascorbate in polysilicone gel)
Study: 11896774
Drug: Inactive polysilicone
Normalized name: Polysilicone-15
DrugBank: Polysilicone-15 (DB11271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive polysilicone gel base (control)
Study: 6777178
Drug: Tocainide 400
Normalized name: tocainide 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide 400 mg every 8 h
Study: 6777178
Drug: Tocainide (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocainide (after 6 months treatment)
Study: 21492237
Drug: Implant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant treatment in patients with OLP
Study: 20497755
Drug: Etanercept (TNF-alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (TNF-alpha receptor antagonist), administered twice weekly for 44 weeks
Study: 15751771
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg, twice daily
Study: 9571600
Drug: Percutaneous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous estradiol (pE2) 1.5 mg/day
Study: 21319007
Drug: Oral estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estriol (E3) 2 mg/day
Study: 9571600
Drug: Percutaneous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous estradiol (pE2) 1.5 mg/day (3rd year follow-up)
Study: 24579474
Drug: BIFICO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIFICO therapy for 4 consecutive days
Study: 14559889
Drug: Pharmaceutical industry-sponsored
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical industry-sponsored trial
Study: 7981178
Drug: lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin 40 mg twice daily
Study: 7981178
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets twice daily
Study: 6587757
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg thrice daily)
Study: 4570671
Drug: Propranolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (100 mg thrice daily)
Study: 4570671
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (20 mg thrice daily)
Study: 28267354
Drug: Body size-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body size-specific organ and effective doses calculated using the National Cancer Institute CT (NCICT) dosimetry program.
Study: 28267354
Drug: Reference phantom-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference phantom-based dose calculation.
Study: 28267354
Drug: Effective dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective dose calculations for body size-specific groups.
Study: 21516735
Drug: lornoxicam (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: lornoxicam (8 or 12 mg/daily) for 15 days in addition to standard treatment
Study: 16168782
Drug: Zinc (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (70 mg) weekly for 12 months
Study: 2486813
Drug: Essential phospholipid
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential phospholipid choline capsules (EPLC) for a six weeks period
Study: 2486813
Drug: Vitamin B
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B complex capsules
Study: 1007830
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg perorally
Study: 1007830
Drug: Atropine sulphate
Normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulphate infusion
Study: 28790141
Drug: Amoxicillin-clavulanate (40/5.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (40/5.7 mg/kg per day)
Study: 25872631
Drug: Mouthwash containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash containing high-molecular-weight component of cranberry (3 mg/ml)
Study: 21641580
Drug: Internet guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet guided self-help treatment programme based on CBT for 6 months with a 6-month follow-up
Study: 19799568
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment in non-VA EDs
Study: 19799568
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment in VA EDs
Study: 17038141
Drug: Verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 240 mg daily in three divided doses for 3 days before cardioversion and 1 week after
Study: 17038141
Drug: Verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 240 mg daily
Study: 17038141
Drug: Usual medication
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medication (Control)
Study: 9294380
Drug: Systemic behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic behavior family therapy (SBFT)
Study: 9294380
Drug: Individual nondirective
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual nondirective supportive therapy (NST)
Study: 8095622
Drug: SPf66 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66 vaccine (n = 738)
Study: 3527555
Drug: 2 X
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 X 500 mg acetylsalicylic acid and 3 X 75 mg dipyridamole per day (treated group)
Study: 3527555
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without medication
Study: 23553534
Drug: Intravenous zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zanamivir 600 mg
Study: 29566543
Drug: Beetroot-based gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot-based gel (BG) supplementation
Study: 29566543
Drug: Nitrate-depleted gel
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-depleted gel (PLA)
Study: 18676516
Drug: Video game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video game intervention addressing cancer treatment and care
Study: 15995847
Drug: Sodium fusidate
Normalized name: Sodium fusidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium fusidate (fusidin; 500 mg orally three times daily for 4 weeks, then the same dose for two consecutive weeks a month followed by 2 weeks a month without the drug for 20 weeks)
Study: 12795777
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of 500 mg clarithromycin tablet
Study: 12795777
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of 500 mg clarithromycin tablet
Study: 10332969
Drug: Self-administered joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered joint counts (JC)
Study: 26728978
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g RUTF/day
Study: 22111330
Drug: Candesartan and
Normalized name: candesartan and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan and amlodipine (combination therapy)
Study: 15277162
Drug: Basic diet
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic diet (BD) with low calcium (224 mg Ca/d)
Study: 15277162
Drug: BD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD with milk (826 mg Ca/d)
Study: 15277162
Drug: BD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD with calcium lactate (802 mg Ca/d)
Study: 15277162
Drug: BD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD with milk mineral isolate (801 mg Ca/d)
Study: 11673021
Drug: Warfarin (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (2.5, 5 or 7.5 mg/day) plus levetiracetam 1000 mg bid
Study: 11673021
Drug: Warfarin (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (2.5, 5 or 7.5 mg/day) plus placebo
Study: 7932170
Drug: Ethacrynic acid
Normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethacrynic acid (EA) 100 mg administered intravenously (i.v.)
Study: 7932170
Drug: Ethacrynic acid
Normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethacrynic acid (EA) 100 mg administered orally (p.o.)
Study: 7932170
Drug: Ethacrynic acid
Normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethacrynic acid (EA) administered by both routes
Study: 7932170
Drug: Ethacrynic acid
Normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethacrynic acid (EA) administered intravenously (i.v.)
Study: 3501375
Drug: Continuous prophylaxis
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous prophylaxis with trimethoprim-sulfamethoxazole (5-25 mg/kg/day/p.o.)
Study: 3501375
Drug: Intermittent prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent prophylaxis with trimethoprim-sulfamethoxazole (3 days/week, 5-25 mg/kg/day/p.o.)
Study: 22877848
Drug: Temozolomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (200 mg/m² on days 1-5 of every 28 days for up to six cycles)
Study: 22877848
Drug: Hypofractionated radiotherapy
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiotherapy (34.0 Gy administered in 3.4 Gy fractions over 2 weeks)
Study: 22877848
Drug: Temozolomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (200 mg/m²)
Study: 16091766
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral 800 IU (727 mg) of alpha‐tocopherol and 500 mg of vitamin C (n = 24)
Study: 16091766
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 24)
Study: 12204662
Drug: Integration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integration of biological response assessment
Study: 10519481
Drug: Betaxolol hydrochloride
Normalized name: Betaxolol Hydrochloride
DrugBank: Betaxolol (DB00195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaxolol hydrochloride ophthalmic solution 0.5%
Study: 7735340
Drug: Fat counseling
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat counseling (20 g/day fat reduction)
Study: 2404555
Drug: Radiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy and combination chemotherapy (cyclophosphamide, Adriamycin, methotrexate, procarbazine)
Study: 7369096
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin (500 units by intravenous infusion every 12 hours)
Study: 7369096
Drug: Fully anticoagulated
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully anticoagulated group (heparin by intravenous infusion and warfarin sodium to maintain a whole blood clotting time of 30 to 90 minutes and a prothrombin index of 10% to 35%)
Study: 31202468
Drug: Deferiprone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone (30 mg/kg per day divided into two equal doses)
Study: 20963404
Drug: Tipranavir/ritonavir (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipranavir/ritonavir (500 mg with 200 mg ritonavir, steady state)
Study: 20963404
Drug: Valacyclovir (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (single dose)
Study: 15808927
Drug: Standardized test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized test with 250 ml fluid meal (250 kcal: 9.4 g protein, 34.4 g carbohydrates, and 8.3 g fat) at admission
Study: 15808927
Drug: Standardized test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized test with 250 ml fluid meal after partial weight gain (2.8 +/- 0.1 kg; BMI 16.1 +/- 0.3 kg/m2)
Study: 15808927
Drug: Standardized test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized test with 250 ml fluid meal at discharge (weight gain: 7.6 +/- 0.5 kg; BMI 17.9 +/- 0.4 kg/m2)
Study: 1960553
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin‐3 (rhIL‐3) administered by a single intravenous (IV) bolus injection followed by subcutaneous (SC) injections once daily from day 2 to 15 at doses of 60, 125, 250, and 500 micrograms/m2
Study: 31426321
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (400 mg/day for 3 weeks)
Study: 28480762
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tenofovir disoproxil fumarate, 300 mg lamivudine, 400/100 mg lopinavir/ritonavir
Study: 28480762
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tenofovir disoproxil fumarate, 300 mg lamivudine, 400 mg nevirapine
Study: 19287011
Drug: Ganciclovir (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir (6 mg/kg iv every 12 h for 6 weeks)
Study: 15684260
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (0.2% ropivacaine and 0.003% morphine)